Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Altered regulation of extrinsic apoptosis pathway in HCV-infected HCC cells enhances susceptibility to mapatumumab-induced apoptosis.

Zhang X, Frank AC, Gille CM, Daucher M, Kabat J, Becker S, Lempicki RA, Cortez KJ, Polis MA, Subramanian GM, Kottilil S.

Hepatol Res. 2009 Dec;39(12):1178-89. doi: 10.1111/j.1872-034X.2009.00568.x.

PMID:
19788693
2.

Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin.

Belyanskaya LL, Marti TM, Hopkins-Donaldson S, Kurtz S, Felley-Bosco E, Stahel RA.

Mol Cancer. 2007 Oct 22;6:66.

3.

Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.

Maddipatla S, Hernandez-Ilizaliturri FJ, Knight J, Czuczman MS.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4556-64.

4.

Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels.

Nawrocki ST, Carew JS, Douglas L, Cleveland JL, Humphreys R, Houghton JA.

Cancer Res. 2007 Jul 15;67(14):6987-94.

5.

Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib.

Luster TA, Carrell JA, McCormick K, Sun D, Humphreys R.

Mol Cancer Ther. 2009 Feb;8(2):292-302. doi: 10.1158/1535-7163.MCT-08-0918.

6.

Enhancement of lexatumumab-induced apoptosis in human solid cancer cells by Cisplatin in caspase-dependent manner.

Wu XX, Kakehi Y.

Clin Cancer Res. 2009 Mar 15;15(6):2039-47. doi: 10.1158/1078-0432.CCR-08-2667.

7.

Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma.

Yamamoto T, Nagano H, Sakon M, Wada H, Eguchi H, Kondo M, Damdinsuren B, Ota H, Nakamura M, Wada H, Marubashi S, Miyamoto A, Dono K, Umeshita K, Nakamori S, Yagita H, Monden M.

Clin Cancer Res. 2004 Dec 1;10(23):7884-95.

8.

Different apoptotic regulation of TRAIL-caspase pathway in HBV- and HCV-related hepatocellular carcinoma.

Yano Y, Hayashi Y, Nakaji M, Nagano H, Seo Y, Ninomiya T, Yoon S, Wada A, Hirai M, Kim SR, Yokozaki H, Kasuga M.

Int J Mol Med. 2003 Apr;11(4):499-504.

PMID:
12632104
9.

TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors.

Stadel D, Mohr A, Ref C, MacFarlane M, Zhou S, Humphreys R, Bachem M, Cohen G, Möller P, Zwacka RM, Debatin KM, Fulda S.

Clin Cancer Res. 2010 Dec 1;16(23):5734-49. doi: 10.1158/1078-0432.CCR-10-0985.

11.

RIP1 is required for IAP inhibitor-mediated sensitization for TRAIL-induced apoptosis via a RIP1/FADD/caspase-8 cell death complex.

Abhari BA, Cristofanon S, Kappler R, von Schweinitz D, Humphreys R, Fulda S.

Oncogene. 2013 Jul 4;32(27):3263-73. doi: 10.1038/onc.2012.337.

PMID:
22890322
12.

COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis.

Yamanaka Y, Shiraki K, Inoue T, Miyashita K, Fuke H, Yamaguchi Y, Yamamoto N, Ito K, Sugimoto K, Nakano T.

Int J Mol Med. 2006 Jul;18(1):41-7.

PMID:
16786154
14.
15.

Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer.

Trarbach T, Moehler M, Heinemann V, Köhne CH, Przyborek M, Schulz C, Sneller V, Gallant G, Kanzler S.

Br J Cancer. 2010 Feb 2;102(3):506-12. doi: 10.1038/sj.bjc.6605507.

16.

The cyclin-dependent kinase inhibitor flavopiridol sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis.

Miyashita K, Shiraki K, Fuke H, Inoue T, Yamanaka Y, Yamaguchi Y, Yamamoto N, Ito K, Sugimoto K, Nakano T.

Int J Mol Med. 2006 Aug;18(2):249-56.

PMID:
16820931
17.
18.

Human hepatocellular carcinoma cells resist to TRAIL-induced apoptosis, and the resistance is abolished by cisplatin.

Shin EC, Seong YR, Kim CH, Kim H, Ahn YS, Kim K, Kim SJ, Hong SS, Park JH.

Exp Mol Med. 2002 May 31;34(2):114-22.

19.

TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5.

Lemke J, Noack A, Adam D, Tchikov V, Bertsch U, Röder C, Schütze S, Wajant H, Kalthoff H, Trauzold A.

J Mol Med (Berl). 2010 Jul;88(7):729-40. doi: 10.1007/s00109-010-0619-0. Erratum in: J Mol Med. 2011 Apr;89(4):423.

PMID:
20354842
20.

Human herpesvirus 7 induces the functional up-regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) coupled to TRAIL-R1 down-modulation in CD4(+) T cells.

Secchiero P, Mirandola P, Zella D, Celeghini C, Gonelli A, Vitale M, Capitani S, Zauli G.

Blood. 2001 Oct 15;98(8):2474-81.

Supplemental Content

Support Center